Compositions and methods for treating insomnia
AssigneeEisai R&D Management Co., Ltd.
InventorsMargaret Moline, Gina Pastino, Yurie Akimoto, Yasuhiro Zaima, Nobuya Suzuki, Nobuo Yoshida
Life of this patent
Estimating the term…
Abstract
In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
Claims13
An oral dosage form comprising a therapeutically effective amount of compound A and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is a single daily dose of about 2.5 mg to about 10 mg that achieves a mean Cmax of from about 3.0 ng/ml to about 7.2 ng/ml for each 1 mg of compound A after administration to human subjects, wherein said compound A is (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide represented by the following formula:
Dependencies are inferred from the claim text.